Lysosomal cathepsins and their regulation in aging and neurodegeneration

Ageing Research Reviews

Volumn 32, Issue , 2016, Pages 22-37

  Stoka, Veronika ^a,b   Turk, Vito ^a,b   Turk, Boris ^a,c,d  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b J Stefan International Postgraduate School   (Slovenia)

^c Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Aging; Alzheimer's disease; Cathepsin D; Cystatin; Cysteine cathepsin; EPM 1; Neuronal ceroid lipofuscinosis

Indexed keywords

ASPARTIC PROTEINASE; CATHEPSIN; CATHEPSIN D; CYSTATIN C; CYSTEINE; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; EPM1 PROTEIN; LYSOSOME ENZYME; POLYGLUTAMINE; PROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; ENZYME MECHANISM; ENZYME SPECIFICITY; HUMAN; HUNTINGTON CHOREA; LYSOSOME; NERVE DEGENERATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; VASCULAR AMYLOIDOSIS; ANIMAL; BRAIN; ENZYMOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; AUTOPHAGY; BRAIN; CATHEPSINS; HUMANS; LYSOSOMES; NEURONAL CEROID-LIPOFUSCINOSES;

EID: 84965071473     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2016.04.010     Document Type: Review

References (266)

1. Abrahamson, M., Grubb, A., Increased body temperature accelerates aggregation of the Leu-68– > Gln mutant cystatin C: the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 1416–1420.
2. Abrahamson, M., Barrett, A.J., Salvesen, G., Grubb, A., Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 261 (1986), 11282–11289.
3. Abrahamson, M., Alvarez-Fernandez, M., Nathanson, C.M., Cystatins. Biochem. Soc. Symp. 70 (2003), 179–199.
4. Aits, S., Jäättelä, M., Lysosomal cell death at a glance. J. Cell Sci. 126 (2013), 1905–1912.
5. Al-Khunaizi, M., Luke, C.J., Askew, Y.S., Pak, S.C., Askew, D.J., Cataltepe, S., Miller, D., Mills, D.R., Tsu, C., Brömme, D., Irving, J.A., Whisstock, J.C., Silverman, G.A., The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry 41 (2002), 3189–3199.
6. Almeida, P.C., Nantes, I.L., Chagas, J.R., Rizzi, C.C.A., Faljoni-Alario, A., Carmona, E., Julianoi, L., Nader, H.B., Tersariol, I.L.S., Cathepsin B activity regulation: heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation. J. Biol. Chem. 276 (2001), 944–951.
7. Alvarez-Fernandez, M., Barrett, A.J., Gerhartz, B., Dando, P.M., Ni, J., Abrahamson, M., Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem. 274 (1999), 19195–19203.
8. Anderson, G.W., Goebel, H.H., Simonati, A., Human pathology in NCL. Biochim. Biophys. Acta 1832 (2013), 1807–1826.
9. Appelqvist, H., Wäster, P., Kågedal, K., Öllinger, K., The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell. Biol. 5 (2013), 214–226.
10. Ashkenazi, A., Salvesen, G., Regulated cell death: signaling and mechanisms. Annu. Rev. Cell Dev. Biol. 30 (2014), 337–356.
11. Awano, T., Katz, M.L., O'Brien, D.P., Taylor, J.F., Evans, J., Khan, S., Sohar, I., Lobel, P., Johnson, G.S., A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 87 (2006), 341–348.
12. Bae, E.J., Yang, N.Y., Lee, C., Kim, S., Lee, H.J., Lee, S.J., Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates. Cell Death Dis., 6, 2015, e1901.
13. Banay-Schwartz, M., Bracco, F., DeGuzman, T., Lajtha, A., Developmental changes in the breakdown of brain tubulin by cerebral cathepsin D. Neurochem. Res. 8 (1983), 51–61.
14. Banay-Schwartz, M., DeGuzman, T., Kenessey, A., Palkovits, M., Lajtha, A., The distribution of cathepsin D activity in adult and aging human brain regions. J. Neurochem. 58 (1992), 2207–2211.
15. Barrett, A.J., Kembhavi, A.A., Brown, M.A., Kirschke, H., Knight, C.G., Tamai, M., Hanada, K., L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201 (1982), 189–198.
16. Beckman, M., Freeman, C., Parish, C.R., Small, D.H., Activation of cathepsin D by glycosaminoglycans. FEBS J. 276 (2009), 7343–7352.
17. Bednarski, E., Lynch, G., Cytosolic proteolysis of (by cathepsin D in hippocampus following suppression of cathepsins B and L. J. Neurochem. 67 (1996), 1846–1855.
18. Bednarski, E., Ribak, C.E., Lynch, G., Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus. J. Neurosci. 17 (1997), 4006–4021.
19. Benuck, M., Banay-Schwartz, M., DeGuzman, T., Lajtha, A., Changes in brain protease activity in aging. J. Neurochem. 67 (1996), 2019–2029.
20. Bernstein, H.G., Kirschke, H., Wiederanders, B., Schmidt, D., Rinne, A., Antigenic expression of cathepsin B in aged human brain. Brain Res. Bull. 24 (1990), 543–549.
21. Berven, L., Johansen, H.T., Solberg, R., Kolset, S.O., Samuelsen, A.B.C., Autoactivation of prolegumain is accelerated by glycosaminoglycans. Biochimie 95 (2013), 772–781.
22. Bevec, T., Stoka, V., Pungerčič, G., Dolenc, I., Turk, V., Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J. Exp. Med. 183 (1996), 1331–1338.
23. Bhutani, N., Piccirillo, R., Hourez, R., Venkatraman, P., Goldberg, A.L., Cathepsins L and Z are critical in degrading polyglutamine-containing proteins within lysosomes. J. Biol. Chem. 287 (2012), 17471–17482.
24. Bi, X., Yong, A.P., Zhou, J., Gall, C.M., Lynch, G., Regionally selective changes in brain lysosomes occur in the transition from young adulthood to middle age in rats. Neuroscience 97 (2000), 395–404.
25. Biniossek, M.L., Nägler, D.K., Becker-Pauly, C., Schilling, O., Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 10 (2011), 5363–5373.
26. Bocock, J.P., Edgell, C.J.S., Marr, H.S., Erickson, A.H., Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L. Eur. J. Biochem 270 (2003), 4008–4015.
27. Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J., Turk, V., The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J. 7 (1988), 2593–2599.
28. Bonneh-Barkay, D., Wiley, C.A., Brain extracellular matrix in neurodegeneration. Brain Pathol. 19 (2009), 573–585.
29. Borgs, L., Malgrange, B., Godin, J.D., Nguyen, L., Huntington's disease: from the physiological function of huntingtin to the disease. Tunali, N.E., (eds.) Huntington's Disease—Core Concepts and Current Advances, 2012, INTECH Open Access Publisher.
30. Boya, P., Kroemer, G., Lysosomal membrane permeabilization in cell death. Oncogene 27 (2008), 6434–6451.
31. Brix, K., Dunkhorst, A., Mayer, K., Jordans, S., Cysteine cathepsins: cellular roadmap to different functions. Biochimie 90 (2008), 194–207.
32. Butinar, M., Prebanda, M.T., Rajković, J., Jerič, B., Stoka, V., Peters, C., Reinheckel, T., Krüger, A., Turk, V., Turk, B., Vasiljeva, O., Stefin B deficiency reduces tumor growth via sensitization of tumor cells to oxidative stress in a breast cancer model. Oncogene 33 (2014), 3392–3400.
33. Cárcel-Trullols, J., Kovács, A.D., Pearce, D.A., Cell biology of the NCL proteins: what they do and don't do. Biochim. Biophys. Acta 1852 (2015), 2242–2255.
34. Caglič, D., Pungerčar, J.R., Pejler, G., Turk, V., Turk, B., Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions. J. Biol. Chem. 282 (2007), 33076–33085.
35. Cataldo, A.M., Nixon, R.A., Enzymatically active lysomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990), 3861–3865.
36. Čeru, S., Konjar, S., Maher, K., Repnik, U., Krizaj, I., Bencina, M., Renko, M., Nepveu, A., Zerovnik, E., Turk, B., Kopitar-Jerala, N., Stefin B interacts with histones and cathepsin L in the nucleus. J. Biol. Chem. 285 (2010), 10078–10086.
37. Choe, Y., Leonetti, F., Greenbaum, D.C., Lecaille, F., Bogyo, M., Bromme, D., Ellman, J.A., Craik, C.S., Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281 (2006), 12824–12832.
38. Ciechanover, A., Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim. Biophys. Acta 1824 (2012), 3–13.
39. Cipollini, E., Riccio, M., Di Giaimo, R., Dal Piaz, F., Pulice, G., Catania, S., Caldarelli, I., Dembic, M., Santi, S., Melli, M., Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo. Biochim. Biophys. Acta 1783 (2008), 312–322.
40. Cirman, T., Orešić, K., Droga Mazovec, G., Turk, V., Reed, J.C., Myers, R.M., Salvesen, G.S., Turk, B., Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem. 279 (2004), 3578–3587.
41. Cook, C., Stankowski, J.N., Carlomagno, Y., Stetler, C., Petrucelli, L., Acetylation: a new key to unlock tau's role in neurodegeneration. Alzheimers Res. Ther., 6, 2014, 29.
42. Coulombe, R., Grochulski, P., Sivaraman, J., Ménard, R., Mort, J.S., Cygler, M., Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J. 15 (1996), 5492–5503.
43. Crabtree, D., Dodson, M., Ouyang, X., Boyer-Guittaut, M., Liang, Q., Ballestas, M.E., Fineberg, N., Zhang, J., Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J. Neurochem. 128 (2014), 950–961.
44. Cuervo, A.M., Dice, J.F., How do intracellular proteolytic systems change with age?. Front. Biosci. 3 (1998), d25–43.
45. Cuervo, A.M., Dice, J.F., When lysosomes get old. Exp. Gerontol. 35 (2000), 119–131.
46. Cuervo, A.M., Autophagy: many paths to the same end. Mol. Cell. Biochem. 263 (2004), 55–72.
47. Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H., Saftig, P., Woulfe, J., Feany, M.B., Myllykangas, L., Schlossmacher, M.G., Tyynelä, J., Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol. Brain, 2, 2009, 5.
48. Cygler, M., Sivaraman, J., Grochulski, P., Coulombe, R., Storer, A.C., Mort, J.S., Structure of rat procathepsin B: Model for inhibition of cysteine protease activity by the proregion. Structure 4 (1996), 405–416.
49. Dahl, S.W., Halkier, T., Lauritzen, C., Dolenc, I., Pedersen, J., Turk, V., Turk, B., Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry 40 (2001), 1671–1678.
50. Danial, N.N., Korsmeyer, S.J., Cell death: critical control points. Cell 116 (2004), 205–219.
51. Deaton, D.N., Kumar, S., 6: Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Prog. Med. Chem. 42 (2004), 245–375.
52. Deiss, L.P., Galinka, H., Berissi, H., Cohen, O., Kimchi, A., Cathepsin D protease mediates programmed cell death induced by interferon-γ, Fas/APO-1 and TNF-α. EMBO J. 15 (1996), 3861–3870.
53. de Duve, C., Pressman, B.C., Gianetto, R., Wattiaux, R., Appelmans, F., Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem. J. 60 (1955), 604–617.
54. de Duve, C., Lysosomes revisited. Eur. J. Biochem. 137 (1983), 391–397.
55. de Duve, C., The lysosome turns fifty. Nat. Cell Biol. 7 (2005), 847–849.
56. Di Giaimo, R., Riccio, M., Santi, S., Galeotti, C., Ambrosetti, D.C., Melli, M., New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B. Hum. Mol. Genet. 11 (2002), 2941–2950.
57. Dieckmann, T., Mitschang, L., Hofmann, M., Kos, J., Turk, V., Auerswald, E.A., Jaenicke, R., Oschkinat, H., The structures of native phosphorylated chicken cystatin and of a recombinant unphosphorylated variant in solution. J. Mol. Biol. 234 (1993), 1048–1059.
58. Dorn, A., Müller, A., Kirschke, H., Wiederanders, B., Bernstein, H.G., Immunohistochemical analysis of the distribution of cathepsin D throughout human nervous system with reference to developmental aspects. Biomed. Biochim. Acta 45 (1986), 1457–1460.
59. Droga-Mazovec, G., Bojič, L., Petelin, A., Ivanova, S., Romih, R., Repnik, U., Salvesen, G.S., Stoka, V., Turk, V., Turk, B., Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 283 (2008), 19140–19150.
60. Duarte, A.J., Ribeiro, D., Chaves, J., Amaral, O., Characterization of a rare Unverricht-Lundborg disease mutation. Mol. Genet. Metab. Rep. 4 (2015), 68–71.
61. Duncan, E.M., Muratore-Schroeder, T.L., Cook, R.G., Garcia, B.A., Shabanowitz, J., Hunt, D.F., Allis, C.D., Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 135 (2008), 284–294.
62. Engh, R.A., Dieckmann, T., Bode, W., Auerswald, E.A., Turk, V., Huber, R., Oschkinat, H., Conformational variability of chicken cystatin: comparison of structures determined by X-ray diffraction and NMR spectroscopy. J. Mol. Biol. 234 (1993), 1060–1069.
63. Fabio, R.D., Moro, F., Pestillo, L., Meschini, M.C., Pezzini, F., Doccini, S., Casali, C., Pierelli, F., Simonati, A., Santorelli, F.M., Pseudo-dominant inheritance of a novel CTSF mutation associated with type B Kufs disease. Neurology 83 (2014), 1769–1770.
64. Fairhead, M., Kelly, S.M., van der Walle, C.F., A heparin binding motif on the pro-domain of human procathepsin L mediates zymogen destabilization and activation. Biochem. Biophys. Res. Commun. 366 (2008), 862–867.
65. Felbor, U., Kessler, B., Mothes, W., Goebel, H.H., Ploegh, H.L., Bronson, R.T., Olsen, B.R., Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 7883–7888.
66. Fonović, M., Turk, B., Cysteine cathepsins and extracellular matrix degradation. Biochim. Biophys. Acta 1840 (2014), 2560–2570.
67. Fox, T., De Miguel, E., Mort, J.S., Storer, A.C., Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 31 (1992), 12571–12576.
68. Fritchie, K., Siintola, E., Armao, D., Lehesjoki, A.E., Marino, T., Powell, C., Tennison, M., Booker, J.M., Koch, S., Partanen, S., Suzuki, K., Tyynelä, J., Thorne, L.B., Novel mutation and the first prenatal screening of cathepsin D deficiency (CLN10). Acta Neuropathol. 117 (2009), 201–208.
69. Frizler, M., Stirnberg, M., Sisay, M.T., Gutschow, M., Development of nitrile-based peptidic inhibitors of cysteine cathepsins. Curr. Top. Med. Chem. 10 (2010), 294–322.
70. Fujishima, A., Imai, Y., Nomura, T., Fujisawa, Y., Yamamoto, Y., Sugawara, T., The crystal structure of human cathepsin L complexed with E-64. FEBS Lett. 407 (1997), 47–50.
71. Ghiso, J., Jensson, O., Frangione, B., Amyloid fibrils in hereditary cerebral hemorrhage with amyloidosis of Icelandic type is a variant of gamma-trace basic protein (cystatin C). Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 2974–2978.
72. Giacobini, E., Gold, G., Alzheimer disease therapy − Moving from amyloid-β to tau. Nat. Rev. Neurol. 9 (2013), 677–686.
73. Gopalakrishnan, M.M., Grosch, H.W., Locatelli-Hoops, S., Werth, N., Smolenová, E., Nettersheim, M., Sandhoff, K., Hasilik, A., Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. Biochem. J. 383 (2004), 507–515.
74. Goulet, B., Baruch, A., Moon, N.S., Poirier, M., Sansregret, L.L., Erickson, A., Bogyo, M., Nepveu, A., A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 14 (2004), 207–219.
75. Groth-Pedersen, L., Jäättelä, M., Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett. 332 (2013), 265–274.
76. Guay, J., Falgueyret, J.P., Ducret, A., Percival, M.D., Mancini, J.A., Potency and selectivity of inhibition of cathepsin K: L and S by their respective propeptides. Eur. J. Biochem. 267 (2000), 6311–6318.
77. Gunčar, G., Podobnik, M., Pungerčar, J., Štrukelj, B., Turk, V., Turk, D., Crystal structure of porcine cathepsin H determined at 2.1 Å resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure 6 (1998), 51–61.
78. Gunčar, G., Pungerčič, G., Klemenčič, I., Turk, V., Turk, D., Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 18 (1999), 793–803.
79. Gunčar, G., Klemenčič, I., Turk, B., Turk, V., Karaoglanovic-Carmona, A., Juliano, L., Turk, D., Crystal structure of cathepsin X: A flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease. Structure 8 (2000), 305–313.
80. Haas, U., Sparks, D.L., Cortical cathepsin D activity and immunolocalization in Alzheimer disease critical coronary artery disease, and aging. Mol. Chem. Neuropathol. 29 (1996), 1–14.
81. Hafner, A., Glavan, G., Obermajer, N., Živin, M., Schliebs, R., Kos, J., Neuroprotective role of γ-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell 12 (2013), 604–614.
82. Halle, A., Hornung, V., Petzold, G.C., Stewart, C.R., Monks, B.G., Reinheckel, T., Fitzgerald, K.A., Latz, E., Moore, K.J., Golenbock, D.T., The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9 (2008), 857–865.
83. Haltia, M., Goebel, H.H., The neuronal ceroid-lipofuscinoses: a historical introduction. Biochim. Biophys. Acta 1832 (2013), 1795–1800.
84. Hayashi, Y., Koyanagi, S., Kusunose, N., Okada, R., Wu, Z., Tozaki-Saitoh, H., Ukai, K., Kohsaka, S., Inoue, K., Ohdo, S., Nakanishi, H., The intrinsic microglial molecular clock controls synaptic strength via the circadian expression of cathepsin S. S. Rep, 3, 2013, 2744.
85. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Weber, T., Brunner, J., Krönke, M., Schütze, S., Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18 (1999), 5252–5263.
86. Hersheson, J., Burke, D., Clayton, R., Anderson, G., Jacques, T.S., Mills, P., Wood, N.W., Gissen, P., Clayton, P., Fearnley, J., Mole, S.E., Houlden, H., Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology. Neurology 83 (2014), 1873–1875.
87. Hook, V.Y.H., Kindy, M., Hook, G., Inhibitors of cathepsin B improve memory and reduce β-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, β-secretase site of the amyloid precursor protein. J. Biol. Chem. 283 (2008), 7745–7753.
88. Hook, G., Hook, V., Kindy, M., The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. J. Alzheimers Dis. 26 (2011), 387–408.
89. Hook, G., Yu, J., Toneff, T., Kindy, M., Hook, V., Brain pyroglutamate amyloid-β is produced by cathepsin b and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J. Alzheimers Dis. 41 (2014), 129–149.
90. Houseweart, M.K., Pennacchio, L.A., Vilaythong, A., Peters, C., Noebels, J.L., Myers, R.M., Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J. Neurobiol. 56 (2003), 315–327.
91. Houseweart, M.K., Vilaythong, A., Yin, X.M., Turk, B., Noebels, J.L., Myers, R.M., Apoptosis caused by cathepsins does not require Bid signaling in an in vivo model of progressive myoclonus epilepsy (EPM1). Cell Death Differ. 10 (2003), 1329–1335.
92. Hwang, S.R., Stoka, V., Turk, V., Hook, V.Y.H., The novel bovine serpin endopin 2C demonstrates selective inhibition of the cysteine protease cathepsin L compared to the serine protease elastase, in cross-class inhibition. Biochemistry 44 (2005), 7757–7767.
93. Impens, F., Colaert, N., Helsens, K., Ghesquière, B., Timmerman, E., De Bock, P.J., Chain, B.M., Vandekerckhove, J., Gevaert, K., A quantitative proteomics design for systematic identification of protease cleavage events. Mol. Cell. Proteomics 9 (2010), 2327–2333.
94. Iqbal, K., Liu, F., Gong, C.X., Tau and neurodegenerative disease: the story so far. Nat. Rev. Neurol 12 (2016), 15–27.
95. Ishidoh, K., Kominami, E., Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem. Biophys. Res. Commun. 217 (1995), 624–631.
96. Ivy, G.O., Schottler, F., Wenzel, J., Baudry, M., Lynch, G., Inhibitors of lysosomal enzymes: accumulation of lipofuscin-like dense bodies in the brain. Science 226 (1984), 985–987.
97. Ivy, G.O., Kanai, S., Ohta, M., Smith, G., Sato, Y., Kobayashi, M., Kitani, K., Lipofuscin-like substances accumulate rapidly in brain, retina and internal organs with cysteine protease inhibition. Adv. Exp. Med. Biol. 266 (1989), 31–45 discussion 45-37.
98. Janowski, R., Kozak, M., Jankowska, E., Grzonka, Z., Grubb, A., Abrahamson, M., Jaskolski, M., Human cystatin C an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. 8 (2001), 316–320.
99. Jenko Kokalj, S., Gunčar, G., Štern, I., Morgan, G., Rabzelj, S., Kenig, M., Staniforth, R.A., Waltho, J.P., Žerovnik, E., Turk, D., Essential role of proline isomerization in stefin B tetramer formation. J. Mol. Biol. 366 (2007), 1569–1579.
100. Jerala, R., Žerovnik, E., Kidrič, J., Turk, V., pH-induced conformational transitions of the propeptide of human cathepsin L: A role for a molten globule state in zymogen activation. J. Biol. Chem. 273 (1998), 11498–11504.
101. Jerič, B., Dolenc, I., Mihelič, M., Klarić, M., Zavašnik-Bergant, T., Gunčar, G., Turk, B., Turk, V., Stoka, V., N-terminally truncated forms of human cathepsin F accumulate in aggresome-like inclusions. Biochim. Biophys. Acta 1833 (2013), 2254–2266.
102. Joensuu, T., Kuronen, M., Alakurtti, K., Tegelberg, S., Hakala, P., Aalto, A., Huopaniemi, L., Aula, N., Michellucci, R., Eriksson, K., Lehesjoki, A.E., Cystatin B: Mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur. J. Hum. Genet. 15 (2007), 185–193.
103. Johansson, A.C., Appelqvist, H., Nilsson, C., Kågedal, K., Roberg, K., Öllinger, K., Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15 (2010), 527–540.
104. Jordans, S., Jenko-Kokalj, S., Kühl, N.M., Tedelind, S., Sendt, W., Brömme, D., Turk, D., Brix, K., Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem., 10, 2009.
105. Jung, H., Lee, E.Y., Lee, S.I., Age-related changes in ultrastructural features of cathepsin B- and D-containing neurons in rat cerebral cortex. Brain Res. 844 (1999), 43–54.
106. Katunuma, N., Murata, E., Kakegawa, H., Matsui, A., Tsuzuki, H., Tsuge, H., Turk, D., Turk, V., Fukushima, M., Tada, Y., Asao, T., Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett. 458 (1999), 6–10.
107. Kegel, K.B., Kim, M., Sapp, E., McIntyre, C., Castano, J.G., Aronin, N., DiFiglia, M., Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J. Neurosci. 20 (2000), 7268–7278.
108. Kenessey, A., Banay-Schwartz, M., DeGuzman, T., Lajtha, A., Increase in cathepsin D activity in rat brain in aging. J. Neurosci. Res. 23 (1989), 454–456.
109. Ketscher, A., Ketterer, S., Dollwet-Mack, S., Reif, U., Reinheckel, T., Neuroectoderm-specific deletion of cathepsin D in mice models human inherited neuronal ceroid lipofuscinosis type 10. Biochimie 122 (2016), 219–226.
110. Kikuchi, H., Yamada, T., Furuya, H., Doh-Ura, K., Ohyagi, Y., Iwaki, T., Kira, J.I., Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. Acta Neuropathol. 105 (2003), 462–468.
111. Kim, Y.J., Sapp, E., Cuiffo, B.G., Sobin, L., Yoder, J., Kegel, K.B., Qin, Z.H., Detloff, P., Aronin, N., DiFiglia, M., Lysosomal proteases are involved in generation of N-terminal huntingtin fragments. Neurobiol. Dis 22 (2006), 346–356.
112. Kirschke, H., Wiederanders, B., Bromme, D., Rinne, A., Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J. 264 (1989), 467–473.
113. Koch, S., Molchanova, S.M., Wright, A.K., Edwards, A., Cooper, J.D., Taira, T., Gillingwater, T.H., Tyynelä, J., Morphologic and functional correlates of synaptic pathology in the cathepsin D knockout mouse model of congenital neuronal ceroid lipofuscinosis. J. Neuropathol. Exp. Neurol. 70 (2011), 1089–1096.
114. Koike, M., Nakanishi, H., Saftig, P., Ezaki, J., Isahara, K., Ohsawa, Y., Schulz-Schaeffer, W., Watanabe, T., Waguri, S., Kametaka, S., Shibata, M., Yamamoto, K., Kominami, E., Peters, C., Von Figura, K., Uchiyama, Y., Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci. 20 (2000), 6898–6906.
115. Koike, M., Shibata, M., Waguri, S., Yoshimura, K., Tanida, I., Kominami, E., Gotow, T., Peters, C., Von Figura, K., Mizushima, N., Saftig, P., Uchiyama, Y., Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167 (2005), 1713–1728.
116. Koike, M., Shibata, M., Ezaki, J., Peters, C., Saftig, P., Kominami, E., Uchiyama, Y., Differences in expression patterns of cathepsin C/dipeptidyl peptidase I in normal: pathological and aged mouse central nervous system. Eur. J. Neurosci. 37 (2013), 816–830.
117. Kollmann, K., Uusi-Rauva, K., Scifo, E., Tyynelä, J., Jalanko, A., Braulke, T., Cell biology and function of neuronal ceroid lipofuscinosis-related proteins. Biochim. Biophys. Acta 1832 (2013), 1866–1881.
118. Kolodziejczyk, R., Michalska, K., Hernandez-Santoyo, A., Wahlbom, M., Grubb, A., Jaskolski, M., Crystal structure of human cystatin C stabilized against amyloid formation. FEBS J. 277 (2010), 1726–1737.
119. Kordiš, D., Turk, V., Phylogenomic analysis of the cystatin superfamily in eukaryotes and prokaryotes. BMC Evol. Biol., 9, 2009, 266.
120. Kos, J., Lah, T.T., Cysteine proteinases and their endogenous inhibitors Target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol. Rep. 5 (1998), 1349–1361.
121. Kos, J., Sekirnik, A., Premzl, A., Zavašnik Bergant, V., Langerholc, T., Turk, B., Werle, B., Golouh, R., Repnik, U., Jeras, M., Turk, V., Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp. Cell Res. 306 (2005), 103–113.
122. Kousi, M., Lehesjoki, A.E., Mole, S.E., Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum. Mutat. 33 (2012), 42–63.
123. López-Otín, C., Bond, J.S., Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283 (2008), 30433–30437.
124. López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., The hallmarks of aging. Cell 153 (2013), 1194–1217.
125. Lalioti, M.D., Scott, H.S., Buresi, C., Rossier, C., Bottani, A., Morris, M.A., Malafosse, A., Antonarakis, S.E., Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature 386 (1997), 847–851.
126. Lalioti, M.D., Antonarakis, S.E., Scott, H.S., The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion. Cytogenet. Genome Res. 100 (2003), 213–223.
127. Laurent-Matha, V., Derocq, D., Prebois, C., Katunuma, N., Liaudet-Coopman, E., Processing of human cathepsin D is independent of its catalytic function and auto-activation: involvement of cathepsins L and B. J. Biochem. 139 (2006), 363–371.
128. Lehtinen, M.K., Tegelberg, S., Schipper, H., Su, H., Zukor, H., Manninen, O., Kopra, O., Joensuu, T., Hakala, P., Bonni, A., Lehesjoki, A.E., Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J. Neurosci. 29 (2009), 5910–5915.
129. Lenarčič, B., Krasovec, M., Ritonja, A., Olafsson, I., Turk, V., Inactivation of human cystatin C and kininogen by human cathepsin D. FEBS Lett. 280 (1991), 211–215.
130. Leterrier, J.F., Eyer, J., Age-dependent changes in the ultrastructure and in the molecular composition of rat brain microtubules. J. Neurochem. 59 (1992), 1126–1137.
131. Levy, E., Jaskolski, M., Grubb, A., The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 16 (2006), 60–70.
132. Li, Z., Tyor, W.R., Xu, J., Chao, J., Hogan, E.L., Immunohistochemical localization of kininogen in rat spinal cord and brain. Exp. Neurol. 159 (1999), 528–537.
133. Liang, Q., Ouyang, X., Schneider, L., Zhang, J., Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol. Neurodegener., 6, 2011, 37.
134. Liu, N., Raja, S.M., Zazzeroni, F., Metkar, S.S., Shah, R., Zhang, M., Wang, Y., Brömme, D., Russin, W.A., Lee, J.C., Peter, M.E., Froelich, C.J., Franzoso, G., Ashton-Rickardt, P.G., NF-(B protects from the lysosomal pathway of cell death. EMBO J. 22 (2003), 5313–5322.
135. Lutgens, S.P.M., Cleutjens, K.B.J.M., Daemen, M.J.A.P., Heeneman, S., Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 21 (2007), 3029–3041.
136. Ménard, R., Carmona, E., Takebe, S., Dufour, É., Plouffe, C., Mason, P., Mort, J.S., Autocatalytic processing of recombinant human procathepsin L: Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro. J. Biol. Chem. 273 (1998), 4478–4484.
137. Martin, J.R., Craven, C.J., Jerala, R., Kroon-Žitko, L., Žerovnik, E., Turk, V., Waltho, J.P., The three-dimensional solution structure of human stefin A. J. Mol. Biol. 246 (1995), 331–343.
138. Mason, R.W., Massey, S.D., Surface activation of pro-cathepsin L. Biochem. Biophys. Res. Commun 189 (1992), 1659–1666.
139. Masson, O., Bach, A.S., Derocq, D., Prébois, C., Laurent-Matha, V., Pattingre, S., Liaudet-Coopman, E., Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity?. Biochimie 92 (2010), 1635–1643.
140. Matus, A., Green, G.D.J., Age-related increase in a cathepsin D like protease that degrades brain microtubule-associated proteins. Biochemistry 26 (1987), 8083–8086.
141. McGlinchey, R.P., Lee, J.C., Cysteine cathepsins are essential in lysosomal degradation of α-synuclein. Proc. Natl. Acad. Sci. U. S. A 112 (2015), 9322–9327.
142. McGrath, M.E., Klaus, J.L., Barnes, M.G., Bromme, D., Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol. 4 (1997), 105–109.
143. Metcalf, P., Fusek, M., Two crystal structures for cathepsin D: The lysosomal targeting signal and active site. EMBO J. 12 (1993), 1293–1302.
144. Mi, W., Pawlik, M., Sastre, M., Jung, S.S., Radvinsky, D.S., Klein, A.M., Sommer, J., Schmidt, S.D., Nixon, R.A., Mathews, P.M., Levy, E., Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat. Genet. 39 (2007), 1440–1442.
145. Miller, J.P., Holcomb, J., Al-Ramahi, I., de Haro, M., Gafni, J., Zhang, N., Kim, E., Sanhueza, M., Torcassi, C., Kwak, S., Botas, J., Hughes, R.E., Ellerby, L.M., Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease. Neuron 67 (2010), 199–212.
146. Mizushima, N., Levine, B., Cuervo, A.M., Klionsky, D.J., Autophagy fights disease through cellular self-digestion. Nature 451 (2008), 1069–1075.
147. Mole, S., NCL resource-a gateway for batten disease. 2015 unpublished, http://www.ucl.ac.uk/ncl/mutation.shtml (accessed 15.10.15.).
148. Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E.D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., Gan, L., Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51 (2006), 703–714.
149. Murata, M., Miyashita, S., Yokoo, C., Tamai, M., Hanada, K., Hatayama, K., Towatari, T., Nikawa, T., Katunuma, N., Novel epoxysuccinyl peptides Selective inhibitors of cathepsin B in vitro. FEBS Lett. 280 (1991), 307–310.
150. Musil, D., Zucic, D., Turk, D., Engh, R.A., Mayr, I., Huber, R., Popovic, T., Turk, V., Towatari, T., Katunuma, N., Bode, W., The refined 2.15 Å X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity. EMBO J. 10 (1991), 2321–2330.
151. Nägler, D.K., Zhang, R., Tam, W., Sulea, T., Purisima, E.O., Ménard, R., Human cathepsin X: A cysteine protease with unique carboxypeptidase activity. Biochemistry 38 (1999), 12648–12654.
152. Nakamura, Y., Takeda, M., Suzuki, H., Morita, H., Tada, K., Hariguchi, S., Nishimura, T., Age-dependent change in activities of lysosomal enzymes in rat brain. Mech. Ageing Dev. 50 (1989), 215–225.
153. Nakamura, Y., Takeda, M., Suzuki, H., Morita, H., Tada, K., Hariguchi, S., Nishimura, T., Lysosome instability in aged rat brain. Neurosci. Lett. 97 (1989), 215–220.
154. Nakanishi, H., Wu, Z., Microglia-aging: roles of microglial lysosome- and mitochondria-derived reactive oxygen species in brain aging. Behav. Brain Res. 201 (2009), 1–7.
155. Nakanishi, H., Tominaga, K., Amano, T., Hirotsu, I., Inoue, T., Yamamoto, K., Age-related changes in activities and localizations of cathepsins D E, B, and L in the rat brain tissues. Exp. Neurol. 126 (1994), 119–128.
156. Nakanishi, H., Amano, T., Sastradipura, D.F., Yoshimine, Y., Tsukuba, T., Tanabe, K., Hirotsu, I., Ohono, T., Yamamoto, K., Increased expression of cathepsins E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein. J. Neurochem. 68 (1997), 739–749.
157. Nakanishi, H., Zhang, J., Koike, M., Nishioku, T., Okamoto, Y., Kominami, E., Von Figura, K., Peters, C., Yamamoto, K., Saftig, P., Uchiyama, Y., Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice. J. Neurosci. 21 (2001), 7526–7533.
158. Nakanishi, H., Microglial functions and proteases. Mol. Neurobiol. 27 (2003), 163–176.
159. Needleman, L.A., McAllister, A.K., The major histocompatibility complex and autism spectrum disorder. Dev. Neurobiol. 72 (2012), 1288–1301.
160. Neurath, H., Proteolytic enzymes, past and future. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 10962–10963.
161. Nixon, R.A., Cataldo, A.M., Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J. Alzheimers Dis. 9 (2006), 277–289.
162. Nixon, R.A., Cataldo, A.M., Mathews, P.M., The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem. Res. 25 (2000), 1161–1172.
163. Nixon, R.A., The role of autophagy in neurodegenerative disease. Nat. Med. 19 (2013), 983–997.
164. Nunomura, A., Miyagishi, T., Ultrastructural observations on neuronal lipofuscin (age pigment) and dense bodies induced by a proteinase inhibitor leupeptin, in rat hippocampus. Acta Neuropathol. 86 (1993), 319–328.
165. Offen, D., Barhum, Y., Melamed, E., Embacher, N., Schindler, C., Ransmayr, G., Spinal cord mRNA profile in patients with ALS: Comparison with transgenic mice expressing the human SOD-1 mutant. J. Mol. Neurosci. 38 (2009), 85–93.
166. Ogrinc, T., Dolenc, I., Ritonja, A., Turk, V., Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett. 336 (1993), 555–559.
167. Olson, O.C., Joyce, J.A., Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer 15 (2015), 712–729.
168. Orenstein, S.J., Cuervo, A.M., Changes in lysosomes and their autophagic function in aging: the comparative biology of lysosomal function. Wolf, N.S., (eds.) The Comparative Biology of Aging, 2010, Springer, New York, 201–226.
169. Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S.A., Goutman, S.A., Feldman, E.L., Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat. Rev. Neurol. 11 (2015), 266–279.
170. Palsdottir, A., Snorradottir, A.O., Thorsteinsson, L., Hereditary cystatin C amyloid angiopathy: genetic clinical, and pathological aspects. Brain Pathol. 16 (2006), 55–59.
171. Paulson, H.L., Albin, R.L., Huntington's disease: clinical features and routes to therapy. Lo, D.C., Hughes, R.E., (eds.) Neurobiology of Huntington's Disease: Applications to Drug Discovery, 2011, CRC Press/Taylor & Francis, Boca Raton (FL).
172. Pennacchio, L.A., Lehesjoki, A.E., Stone, N.E., Willour, V.L., Virtaneva, K., Miao, J., D'Amato, E., Ramirez, L., Faham, M., Koskiniemi, M., Warrington, J.A., Norio, R., De La Chapelle, A., Cox, D.R., Myers, R.M., Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271 (1996), 1731–1734.
173. Pennacchio, L.A., Bouley, D.M., Higgins, K.M., Scott, M.P., Noebels, J.L., Myers, R.M., Progressive ataxia: myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat. Genet. 20 (1998), 251–258.
174. Pinto, E., Freitas, J., Duarte, A.J., Ribeiro, I., Ribeiro, D., Lima, J.L., Chaves, J., Amaral, O., Unverricht-Lundborg disease: homozygosity for a new splicing mutation in the cystatin B gene. Epilepsy Res. 99 (2012), 187–190.
175. Podobnik, M., Kuhelj, R., Turk, V., Turk, D., Crystal structure of the wild-type human procathepsin B at 2: 5 Å resolution reveals the native active site of a papain-like cysteine protease zymogen. J. Mol. Biol. 271 (1997), 774–788.
176. Polajnar, M., Zavašnik-Bergant, T., Kopitar-Jerala, N., Tušek-Žnidarič, M., Žerovnik, E., Gain in toxic function of stefin B EPM1 mutants aggregates: correlation between cell death, aggregate number/size and oxidative stress. Biochim. Biophys. Acta 1843 (2014), 2089–2099.
177. Porta, E., Llesuy, S., Monserrat, A.J., Benavides, S., Travacio, M., Changes in cathepsin B and lipofuscin during development and aging in rat brain and heart. Gerontology 41 (1995), 81–93.
178. Qiao, L., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., Yacoubian, T.A., Wilson, S., Xie, Z.L., Speake, L.D., Parks, R., Crabtree, D., Liang, Q., Crimmins, S., Schneider, L., Uchiyama, Y., Iwatsubo, T., Zhou, Y., Peng, L., Lu, Y., Standaert, D.G., Walls, K.C., Shacka, J.J., Roth, K.A., Zhang, J., Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain, 1, 2008, 17.
179. Qin, Z.H., Gu, Z.L., Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol. Sin. 25 (2004), 1243–1249.
180. Qin, Z.H., Wang, Y., Kegel, K.B., Kazantsev, A., Apostol, B.L., Thompson, L.M., Yoder, J., Aronin, N., DiFiglia, M., Autophagy regulates the processing of amino terminal huntingtin fragments. Hum. Mol. Genet. 12 (2003), 3231–3244.
181. Querfurth, H.W., LaFerla, F.M., Alzheimer's disease. N. Engl. Med. 362 (2010), 329–344.
182. Quraishi, O., Storer, A.C., Identification of internal autoproteolytic cleavage sites within the prosegments of recombinant procathepsin B and procathepsin S. Contribution of a plausible unimolecular autoproteolytic event for the processing of zymogens belonging to the papain family. J. Biol. Chem. 276 (2001), 8118–8124.
183. Ratovitski, T., Chighladze, E., Waldron, E., Hirschhorn, R.R., Ross, C.A., Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin. J. Biol. Chem. 286 (2011), 12578–12589.
184. Ravikumar, B., Duden, R., Rubinsztein, D.C., Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11 (2002), 1107–1117.
185. Repnik, U., Stoka, V., Turk, V., Turk, B., Lysosomes and lysosomal cathepsins in cell death. Biochim. Biophys. Acta 1824 (2012), 22–33.
186. Repnik, U., Hafner Česen, M., Turk, B., Lysosomal membrane permeabilization in cell death: concepts and challenges. Mitochondrion, 2014, 49–57.
187. Repnik, U., Starr, A.E., Overall, C.M., Turk, B., Cysteine cathepsins activate ELR chemokines and inactivate non-ELR chemokines. J. Biol. Chem. 290 (2015), 13800–13811.
188. Rinne, R., Saukko, P., Järvinen, M., Lehesjoki, A.E., Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. Ann. Med. 34 (2002), 380–385.
189. Rossi, A., Deveraux, Q., Turk, B., Sali, A., Comprehensive search for cysteine cathepsins in the human genome. Biol. Chem. 385 (2004), 363–372.
190. Rozman Pungerčar, J., Caglič, D., Sajid, M., Dolinar, M., Vasiljeva, O., Požgan, U., Turk, D., Bogyo, M., Turk, V., Turk, B., Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J. 276 (2009), 660–668.
191. Rozman, J., Stojan, J., Kuhelj, R., Turk, V., Turk, B., Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett. 459 (1999), 358–362.
192. Rubinsztein, D.C., The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443 (2006), 780–786.
193. Saftig, P., Peters, C., von Figura, K., Craessaerts, K., Van Leuven, F., De Strooper, B., Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. J. Biol. Chem. 271 (1996), 27241–27244.
194. Samii, A., Nutt, J.G., Ransom, B.R., Parkinson's disease. Lancet 363 (2004), 1783–1793.
195. Santos-Rosa, H., Kirmizis, A., Nelson, C., Bartke, T., Saksouk, N., Cote, J., Kouzarides, T., Histone H3 tail clipping regulates gene expression. Nat. Struct. Mol. Biol. 16 (2009), 17–22.
196. Sapp, E., Schwarz, C., Chase, K., Bhide, P.G., Young, A.B., Penney, J., Vonsattel, J.P., Aronin, N., DiFiglia, M., Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 42 (1997), 604–612.
197. Sato, Y., Suzuki, Y., Ito, E., Shimazaki, S., Ishida, M., Yamamoto, T., Yamamoto, H., Toda, T., Suzuki, M., Suzuki, A., Endo, T., Identification and characterization of an increased glycoprotein in aging: age-associated translocation of cathepsin D. Mech. Ageing Dev. 127 (2006), 771–778.
198. Schechter, I., Berger, A., On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27 (1967), 157–162.
199. Schick, C., Pemberton, P.A., Shi, G.P., Kamachi, Y., Çataltepe, S., Bartuski, A.J., Gornstein, E.R., Brömme, D., Chapman, H.A., Silverman, G.A., Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 37 (1998), 5258–5266.
200. Schilling, O., Overall, C.M., Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat. Biotechnol. 26 (2008), 685–694.
201. Sevenich, L., Pennacchio, L.A., Peters, C., Reinheckel, T., Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biol. Chem. 387 (2006), 885–891.
202. Sevlever, D., Jiang, P., Yen, S.H.C., Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47 (2008), 9678–9687.
203. Shacka, J.J., Klocke, B.J., Young, C., Shibata, M., Olney, J.W., Uchiyama, Y., Saftig, P., Roth, K.A., Cathepsin D deficiency induces persistent neurodegeneration in the absence of bax-dependent apoptosis. J. Neurosci. 27 (2007), 2081–2090.
204. Shimizu, T., Hayashi, Y., Yamasaki, R., Yamada, J., Zhang, J., Ukai, K., Koike, M., Mine, K., Von Figura, K., Peters, C., Saftig, P., Fukuda, T., Uchiyama, Y., Nakanishi, H., Proteolytic degradation of glutamate decarboxylase mediates disinhibition of hippocampal CA3 pyramidal cells in cathepsin D-deficient mice. J. Neurochem. 94 (2005), 680–690.
205. Siintola, E., Partanen, S., Strömme, P., Haapanen, A., Haltia, M., Maehlen, J., Lehesjoki, A.E., Tyynelä, J., Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 129 (2006), 1438–1445.
206. Sivaraman, J., Lalumière, M., Ménard, R., Cygler, M., Crystal structure of wild-type human procathepsin K. Protein Sci. 8 (1999), 283–290.
207. Smith, K.R., Dahl, H.H.M., Canafoglia, L., Andermann, E., Damiano, J., Morbin, M., Bruni, A.C., Giaccone, G., Cossette, P., Saftig, P., Grötzinger, J., Schwake, M., Andermann, F., Staropoli, J.F., Sims, K.B., Mole, S.E., Franceschetti, S., Alexander, N.A., Cooper, J.D., Chapman, H.A., Carpenter, S., Berkovic, S.F., Bahlo, M., Cathepsin F mutations cause Type B Kufs disease: an adult-onset neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22 (2013), 1417–1423.
208. Snir, J.A., Suchy, M., Lawrence, K.S., Hudson, R.H., Pasternak, S.H., Bartha, R., Prolonged In vivo retention of a cathepsin D targeted optical contrast agent in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 48 (2015), 73–87.
209. Snyder, D.S., Whitaker, J.N., Postnatal changes in cathepsin D in rat neural tissue. J. Neurochem. 40 (1983), 1161–1170.
210. Snyder, D.S., Simonis, S., Uzman, B.G., Whitaker, J.N., Rat neural tissue cathepsin D: ultrastructural immunocytochemistry. J. Neurocytol. 14 (1985), 579–596.
211. Sobotič, B., Vizovišek, M., Vidmar, R., Van Damme, P., Gocheva, V., Joyce, J.A., Gevaert, K., Turk, V., Turk, B., Fonović, M., Proteomic identification of cysteine cathepsin substrates shed from the surface of cancer cells. Mol. Cell. Proteomics 14 (2015), 2213–2228.
212. Somoza, J.R., Zhan, H., Bowman, K.K., Yu, L., Mortara, K.D., Palmer, J.T., Clark, J.M., McGrath, M.E., Crystal structure of human cathepsin V. Biochemistry 39 (2000), 12543–12551.
213. Somoza, J.R., Palmer, J.T., Ho, J.D., The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators. J. Mol. Biol. 322 (2002), 559–568.
214. Steinfeld, R., Reinhardt, K., Schreiber, K., Hillebrand, M., Kraetzner, R., Brück, W., Saftig, P., Gärtner, J., Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am. J. Hum. Genet. 78 (2006), 988–998.
215. Stoka, V., Turk, V., Turk, B., Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol. Chem 388 (2007), 555–560.
216. Stubbs, M.T., Laber, B., Bode, W., Huber, R., Jerala, R., Lenarčič, B., Turk, V., The refined 2.4 Å X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 9 (1990), 1939–1947.
217. Sun, B., Zhou, Y., Halabisky, B., Lo, I., Cho, S.H., Mueller-Steiner, S., Devidze, N., Wang, X., Grubb, A., Gan, L., Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60 (2008), 247–257.
218. Sun, T., Turk, V., Turk, B., Kopitar-Jerala, N., Increased expression of stefin B in the nucleus of T98 G astrocytoma cells delays caspase activation. Front. Mol. Neurosci., 5, 2012, 93.
219. Tang, C.H., Lee, J.W., Galvez, M.G., Robillard, L., Mole, S.E., Chapman, H.A., Murine cathepsin F deficiency causes neuronal lipofuscinosis and late-onset neurological disease. Mol. Cell. Biol. 26 (2006), 2309–2316.
220. Towatari, T., Nikawa, T., Murata, M., Yokoo, C., Tamai, M., Hanada, K., Katunuma, N., Novel epoxysuccinyl peptides A selective inhibitor of cathepsin B in vivo. FEBS Lett. 280 (1991), 311–315.
221. Tsuge, H., Nishimura, T., Tada, Y., Asao, T., Turk, D., Turk, V., Katunuma, N., Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Biochem. Biophys. Res. Commun. 266 (1999), 411–416.
222. Tsujimura, A., Taguchi, K., Watanabe, Y., Tatebe, H., Tokuda, T., Mizuno, T., Tanaka, M., Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils. Neurobiol. Dis. 73 (2015), 244–253.
223. Turk, V., Bode, W., The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285 (1991), 213–219.
224. Turk, B., Stoka, V., Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett. 581 (2007), 2761–2767.
225. Turk, B., Turk, V., Lysosomes as suicide bags in cell death: myth or reality?. J. Biol. Chem. 284 (2009), 21783–21787.
226. Turk, B., Dolenc, I., Turk, V., Bieth, J.G., Kinetics of the pH-induced inactivation of human cathepsin L. Biochemistry 32 (1993), 375–380.
227. Turk, B., Čolić, A., Stoka, V., Turk, V., Kinetics of inhibition of bovine cathepsin S by bovine stefin B. FEBS Lett. 339 (1994), 155–159.
228. Turk, B., Dolenc, I., Žerovnik, E., Turk, D., Gubenšek, F., Turk, V., Human cathepsin B is a metastable enzyme stabilized by specific ionic interactions associated with the active site. Biochemistry 33 (1994), 14800–14806.
229. Turk, B., Bieth, J.G., Bjork, I., Dolenc, I., Turk, D., Cimerman, N., Kos, J., Čolić, A., Stoka, V., Turk, V., Regulation of the activity of lysosomal cysteine proteinases by pH-induced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe Seyler 376 (1995), 225–230.
230. Turk, B., Stoka, V., Bjork, I., Boudier, C., Johansson, G., Dolenc, I., Čolić, A., Bieth, J.G., Turk, V., High-affinity binding of two molecules of cysteine proteinases to low- molecular-weight kininogen. Protein Sci. 4 (1995), 1874–1880.
231. Turk, B., Stoka, V., Turk, V., Johansson, G., Cazzulo, J.J., Björk, I., High-molecular-weight kininogen binds two molecules of cysteine proteinases with different rate constants. FEBS Lett. 391 (1996), 109–112.
232. Turk, B., Turk, V., Turk, D., Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem. 378 (1997), 141–150.
233. Turk, D., Gunčar, G., Podobnik, M., Turk, B., Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. 379 (1998), 137–147.
234. Turk, B., Dolenc, I., Lenarčič, B., Križaj, I., Turk, V., Bieth, J.G., Björk, I., Acidic pH as a physiological regulator of human cathepsin L activity. Eur. J. Biochem. 259 (1999), 926–932.
235. Turk, B., Turk, D., Turk, V., Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477 (2000), 98–111.
236. Turk, D., Janjić, V., Štern, I., Podobnik, M., Lamba, D., Dahl, S.W., Lauritzen, C., Pedersen, J., Turk, V., Turk, B., Structure of human dipeptidyl peptidase I (cathepsin C): Exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 20 (2001), 6570–6582.
237. Turk, V., Turk, B., Turk, D., Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20 (2001), 4629–4633.
238. Turk, B., Turk, D., Salvesen, G.S., Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. 8 (2002), 1623–1637.
239. Turk, D., Turk, B., Turk, V., Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery targets?. Biochem. Soc. Symp. 70 (2003), 15–30.
240. Turk, B., Turk, D., Salvesen, G.S., Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Med. Chem. Rev.—Online 2 (2005), 283–297.
241. Turk, V., Stoka, V., Turk, D., Cystatins Biochemical and structural properties, and medical relevance. Front. Biosci. 13 (2008), 5406–5420.
242. Turk, B., Turk, D., Turk, V., Protease signalling: the cutting edge. EMBO J. 31 (2012), 1630–1643.
243. Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., Turk, D., Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824 (2012), 68–88.
244. Turk, B., Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5 (2006), 785–799.
245. Turkenburg, J.P., Lamers, M.B.A.C., Brzozowski, A.M., Wright, L.M., Hubbard, R.E., Sturt, S.L., Williams, D.H., Structure of a Cys25 → Ser mutant of human cathepsin S. Acta Crystallogr. D Biol. Crystallogr. 58 (2002), 451–455.
246. Tyynelä, J., Sohar, I., Sleat, D.E., Gin, R.M., Donnelly, R.J., Baumann, M., Haltia, M., Lobel, P., A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 19 (2000), 2786–2792.
247. Ulbrich, L., Cozzolino, M., Marini, E.S., Amori, I., De Jaco, A., Carrì, M.T., Augusti-Tocco, G., Cystatin B and SOD1: Protein-protein interaction and possible relation to neurodegeneration. Cell. Mol. Neurobiol. 34 (2014), 205–213.
248. Umezawa, H., Low-molecular-weight enzyme inhibitors of microbial origin. Annu. Rev. Microbiol 36 (1982), 75–99.
249. Unanue, E.R., Turk, V., Neefjes, J., Variations in MHC class II antigen processing and presentation in health and disease. Annu. Rev. Immunol., 2016, 10.1146/annurev-immunol-041015-055420 paper is published ahead of print.
250. Vasiljeva, O., Dolinar, M., Rozman Pungerčar, J., Turk, V., Turk, B., Recombinant human procathepsin S is capable of autocatalytic processing at neutral pH in the presence of glycosaminoglycans. FEBS Lett. 579 (2005), 1285–1290.
251. Vizovišek, M., Vidmar, R., Van Quickelberghe, E., Impens, F., Andjelković, U., Sobotič, B., Stoka, V., Gevaert, K., Turk, B., Fonović, M., Fast profiling of protease specificity reveals similar substrate specificities for cathepsins K, L and S. Proteomics 15 (2015), 2479–2490.
252. Von Figura, K., Hasilik, A., Lysosomal enzymes and their receptors. Annu. Rev. Biochem. 55 (1986), 167–193.
253. von Bernhardi, R., Eugenín-von Bernhardi, L., Eugenín, J., Microglial cell dysregulation in brain aging and neurodegeneration. Front. Aging Neurosci., 7, 2015.
254. Watanabe, S., Hayakawa, T., Wakasugi, K., Yamanaka, K., Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death Dis., 5, 2014, e1497.
255. Welss, T., Sun, J., Irving, J.A., Blum, R., Smith, A.I., Whisstock, J.C., Pike, R.N., Von Mikecz, A., Ruzicka, T., Bird, P.I., Abts, H.F., Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 42 (2003), 7381–7389.
256. Wendt, W., Zhu, X.R., Lübbert, H., Stichel, C.C., Differential expression of cathepsin X in aging and pathological central nervous system of mice. Exp. Neurol. 204 (2007), 525–540.
257. Wendt, W., Lübbert, H., Stichel, C.C., Upregulation of cathepsin S in the aging and pathological nervous system of mice. Brain Res. 1232 (2008), 7–20.
258. Wiederanders, B., Kaulmann, G., Schilling, K., Functions of propeptide parts in cysteine proteases. Curr. Protein Pept. Sci. 4 (2003), 309–326.
259. Wisniewski, K.E., Kida, E., Golabek, A.A., Kaczmarski, W., Connell, F., Zhong, N., 1 Neuronal ceroid lipofuscinoses: classification and diagnosis. Adv. Genet. 45 (2001), 1–34.
260. Wootz, H., Weber, E., Korhonen, L., Lindholm, D., Altered distribution and levels of cathepsinD and cystatins in amyotrophic lateral sclerosis transgenic mice: possible roles in motor neuron survival. Neuroscience 143 (2006), 419–430.
261. Wu, Z., Sun, L., Hashioka, S., Yu, S., Schwab, C., Okada, R., Hayashi, Y., McGeer, P.L., Nakanishi, H., Differential pathways for interleukin-1beta production activated by chromogranin A and amyloid beta in microglia. Neurobiol. Aging 34 (2013), 2715–2725.
262. Yu, J.T., Tan, L., Hardy, J., Apolipoprotein e in Alzheimer's disease: An update. Annu. Rev. Neurosci. 37 (2014), 79–100.
263. Zaidi, N., Maurer, A., Nieke, S., Kalbacher, H., Cathepsin D: a cellular roadmap. Biochem. Biophys. Res. Commun. 376 (2008), 5–9.
264. Zhang, Z., Song, M., Liu, X., Kang, S.S., Kwon, I.S., Duong, D.M., Seyfried, N.T., Hu, W.T., Liu, Z., Wang, J.Z., Cheng, L., Sun, Y.E., Yu, S.P., Levey, A.I., Ye, K., Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20 (2014), 1254–1262.
265. Žerovnik, E., Škerget, K., Tušek-Žnidarič, M., Loeschner, C., Brazier, M.W., Brown, D.R., High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation. FEBS J. 273 (2006), 4250–4263.
266. Zoghbi, H.Y., Orr, H.T., Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000), 217–247.